Literature DB >> 17699840

ErbB-dependent signaling as a determinant of trastuzumab resistance.

Rakesh Kumar.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17699840     DOI： 10.1158/1078-0432.CCR-07-1401

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


× No keyword cloud information.
  8 in total

Review 1.  Current controversies in the management of breast cancer.

Authors:  I Tusquets; L García-Estévez; E Adrover; L Calvo; I Alvarez; J García Mata; Y Fernández; M Margueli; M A Seguí; M Muñoz; C Rodríguez; A Rodríguez Lescure; R Colomer; P Gascón; M Martín; E Alba; A Barnadas; A Llombart; J Albanell; A Lluch
Journal:  Clin Transl Oncol       Date:  2010-04       Impact factor: 3.405

Review 2.  The neuregulin family of genes and their multiple splice variants in breast cancer.

Authors:  Nandini V L Hayes; William J Gullick
Journal:  J Mammary Gland Biol Neoplasia       Date:  2008-04-15       Impact factor: 2.673

3.  Monitoring circulating epithelial tumour cells (CETC) to gauge therapy: in patients with disease progression after trastuzumab persisting CETC can be eliminated by combined lapatinib treatment.

Authors:  Oumar Camara; Cornelia Jörke; Ulrike Hammer; Anne Egbe; Carola Rabenstein; Ingo B Runnebaum; Klaus Hoeffken; Katharina Pachmann
Journal:  J Cancer Res Clin Oncol       Date:  2008-10-21       Impact factor: 4.553

4.  Disruption of FOXO3a-miRNA feedback inhibition of IGF2/IGF-1R/IRS1 signaling confers Herceptin resistance in HER2-positive breast cancer.

Authors:  Liyun Luo; Zhijie Zhang; Ni Qiu; Li Ling; Xiaoting Jia; Ying Song; Hongsheng Li; Jiansheng Li; Hui Lyu; Hao Liu; Zhimin He; Bolin Liu; Guopei Zheng
Journal:  Nat Commun       Date:  2021-05-11       Impact factor: 14.919

5.  Herceptin conjugates linked by EDC boost direct tumor cell death via programmed tumor cell necrosis.

Authors:  Jiemiao Hu; Xinli Liu; Dennis Hughes; Francisco J Esteva; Bolin Liu; Joya Chandra; Shulin Li
Journal:  PLoS One       Date:  2011-08-10       Impact factor: 3.240

6.  Protein tyrosine phosphatase SHP-1 sensitizes EGFR/HER-2 positive breast cancer cells to trastuzumab through modulating phosphorylation of EGFR and HER-2.

Authors:  Yifen Wu; Rong Li; Junyi Zhang; Gang Wang; Bin Liu; Xiaofang Huang; Tao Zhang; Rongcheng Luo
Journal:  Onco Targets Ther       Date:  2015-09-14       Impact factor: 4.147

7.  EGFR expression is associated with decreased benefit from trastuzumab in the NCCTG N9831 (Alliance) trial.

Authors:  H Cheng; K Ballman; M Vassilakopoulou; A C Dueck; M M Reinholz; K Tenner; J Gralow; C Hudis; N E Davidson; G Fountzilas; A E McCullough; B Chen; A Psyrri; D L Rimm; E A Perez
Journal:  Br J Cancer       Date:  2014-08-12       Impact factor: 7.640

8.  Structural basis of a novel heterodimeric Fc for bispecific antibody production.

Authors:  Hudie Wei; Haiyan Cai; Yuhao Jin; Pilin Wang; Qingqing Zhang; Yihui Lin; Weixiao Wang; Jinke Cheng; Naiyan Zeng; Ting Xu; Aiwu Zhou
Journal:  Oncotarget       Date:  2017-05-02
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.